Total lung cancers (NSCLC) are one of the most common types of cancer, accounting for about 85% of all lung cancer cases. Effective treatment of this disease requires accurate identification of tumor-specific genetic changes, which significantly affects the available therapeutic options. In this article, we will review the limitations of using single gene testing (SGT) in identifying actionable mutations, versus the substantial benefits of comprehensive genomic profiling (CGP) techniques. We will discuss four clinical cases from a large reference laboratory, where CGP analyses revealed actionable mutations not identified by SGT tests. These cases highlight the importance of achieving a comprehensive understanding of genetic mutations and demonstrate how initial test results can be reversed by adopting a more comprehensive methodology. By analyzing these cases, we aim to emphasize the vital importance of advanced testing models in improving patient outcomes.
The Importance of Identifying Genetic Changes in Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) poses one of the main challenges in cancer treatment due to its genetic and cellular complexities. About 85% of all lung cancer diagnoses fall under this type, which necessitates the importance of accurately screening for tumor-specific genetic changes. This focus on genetic changes is essential for selecting appropriate and effective treatments for individuals. While treatment in the past predominantly relied on toxin-based chemotherapy, the focus has now shifted to targeted therapies that depend on specific genetic changes identified through techniques such as comprehensive genomic profiling (CGP).
With the advancement of scientific research, comprehensive gene testing that can cover a wide range of genetic alterations has become feasible, in contrast to single gene testing (SGT) that may not reveal some critical changes. The importance of identifying genetic changes lies in directly guiding the therapeutic path, leading to improved treatment outcomes and contributing to increased chances of saving patients’ lives.
Challenges Associated with Single Gene Testing (SGT)
Despite the availability of single gene testing techniques, there are numerous limitations associated with them. One of these challenges is the inability to identify some important genetic changes due to restrictions imposed on the scope of testing. For instance, if the testing is not comprehensive, certain types of mutations critical for determining the appropriate treatment may be overlooked. Furthermore, clinical settings relying on single gene testing can lead to the depletion of high-quality tissue samples, making it difficult to conduct future tests.
In one of the analyzed cases, a woman in her forties was identified, and the initial discovery through single gene testing was negative. However, subsequent screenings through comprehensive genomic profiling (CGP) revealed mutations associated with genetic changes, underscoring the significant value of using more comprehensive tests to enhance patients’ chances of receiving appropriate therapeutic interventions.
Benefits of Comprehensive Genomic Profiling (CGP)
The benefits of comprehensive genomic profiling represent a positive step towards achieving treatment accuracy, as the comprehensive testing provides detailed information on genetic changes, allowing doctors to make data-driven decisions. The next-generation sequencing (NGS) technology used in CGP allows for the sequencing of large portions of DNA and RNA, enabling the identification of all significant genetic changes. The new technology can identify mutations, examine tissue, and assess gene expression, all of which contribute to achieving accurate diagnoses and delivering cutting-edge targeted therapies.
An example
A recent case refers to an elderly man suffering from cancer deterioration, where values from single-gene testing showed no actionable mutations. However, comprehensive genomic testing revealed multiple insertions in the EGFR gene, necessitating new treatment options. Additionally, CGP facilitates access to clinical trials for advanced therapeutic options, which could have a significant impact on the patient’s life.
The Contrast Between SGT and CGP Results and Their Impact on Health Managers
Comparisons between single-gene testing results and comprehensive testing show how different tests can lead to entirely different outcomes. In some cases, patients reported that their diagnosis and treatment results were severely impacted due to inaccurate tests. This disparity not only affects the imposed treatments but also the patients’ outlook on their overall medical care. For example, a finding from single-gene testing may yield negative results, while comprehensive testing shows effective options, leading to frustration and emotional exhaustion for individuals relying on initial test results.
Consequently, the ongoing use of comprehensive genomic testing provides a better outcome for patients and gives them renewed hope for maintaining their lives and achieving tangible therapeutic progress. It is essential for health managers and caregivers to incorporate comprehensive genomic testing as a core part of treatment strategies, enhancing the effectiveness of obtaining accurate results based on a deep understanding of genetic data.
The Importance of Integrated Molecular Diagnosis in Lung Cancer Treatment
Lung cancer treatment is increasingly influenced by modern technologies in molecular diagnosis, with Comprehensive Genomic Profiling (CGP) being one of the key tools in guiding treatment and patient care. Patient responses to treatment may vary based on the genetic mutations present in their tumors, making it crucial to analyze genetic mutations accurately. For instance, BRAF V600E mutation has been identified in some cases, allowing the identification of effective therapeutic options. Compared to traditional methods such as gene sequencing that rely on limited technologies, CGP provides a comprehensive display of mutations that modern drugs could benefit from, underscoring the necessity of its use over traditional techniques in advanced stages of lung cancer.
One significant aspect of CGP diagnosis is its ability to identify a variety of genetic alterations that limited gene sequencing tests may miss. Thus, the value of CGP lies in facilitating clinical processes and reducing the need for further testing, which is an interesting feature in areas where tissue sources may be limited. In light of this, it becomes clear that traditional criteria such as single-gene testing (SGT) may not be sufficiently effective given the diagnostic challenges faced.
Challenges Associated with Traditional Genetic Testing
Numerous cases reveal how SGT techniques can fail to detect critical mutations, raising questions about their efficacy in diagnosing advanced lung cancer. For instance, in one case, SGT was unable to identify the presence of significant ALK fusions, which represent essential triggers for tumor growth. In other cases, traditional PCR tests could not detect EGFR exon 20 insertions, which are complex mutations responsible for patient treatment responses. These issues illustrate that the challenges associated with using SGT include poor performance in detecting a number of mutations and the unsuitability of testing methodologies for any uncommon or complex mutations.
Moreover, SGT shows clear limitations in detecting complex genetic fusions, where SGT screenings often struggle to identify more complicated structural changes. This gap means that traditional screenings will not provide accurate information about the genetic status of the tumor and thus cannot be relied upon to devise appropriate treatment strategies. Therefore, CGP is considered a more reliable option, as it facilitates the discovery of all existing mutations, including those that may affect treatment.
Trends
Towards Precision Medicine in Lung Cancer Treatment
The success of targeted therapy for lung cancer requires a comprehensive understanding of genetic biomarkers, which represent a key tool in formulating appropriate treatment strategies. The role of precision medicine lies in identifying genetic mutations and guiding physicians in selecting the most effective therapies. One example is the ability of CGP to consider multiple genetic alterations such as EGFR insertions and MET methylation changes, which can affect treatment options. The use of CGP emphasizes the importance of thorough screening, which can open doors to new treatment opportunities, increasing response rates and survival times for patients.
Advancements in research and the development of precision medicine-based therapies can significantly contribute to improving therapeutic outcomes. By early identification of key mutations, patients have higher chances to benefit from targeted treatments, achieving a substantial increase in treatment efficacy. It is essential for oncologists, physicians, and genetic specialists to collaborate in providing the necessary support and tools to optimally devise targeted therapeutic strategies based on CGP data.
Ongoing Research and Interdisciplinary Collaboration
Ongoing research and collaboration among different medical science specialties are vital components in enhancing precision and effective treatment for lung cancer. Utilizing CGP in clinical settings necessitates sufficient knowledge about new mutations and educating physicians on how to present oncology as an advanced treatment option. There should be an investment in scientific research to develop new ways to evaluate complex genetic data and present it in a manner that can be understood by physicians, facilitating appropriate therapeutic decision-making.
The success of CGP relies heavily on the ability to interpret results effectively, which requires support from scientists and researchers to monitor treatment developments and apply them to patients effectively. Continuous discussions and research contribute to enhancing physicians’ understanding of targeted treatment strategies and ensuring the ongoing development of methods used to analyze mutations and monitor their evolution.
Challenges of Personalized Treatment for Non-Small Cell Lung Cancer
The challenges facing the use of comprehensive genetic profiling in the treatment of non-small cell lung cancer (NSCLC) are manifold and complex. Despite the potential benefits of personalized therapy, especially in improving patient outcomes, there are obstacles related to testing methods and the interaction between physician and patient. Conflicting results between tests may lead to confusion and frustration for patients. For instance, if a single genetic test (SGT) fails to detect significant genetic changes such as ALK fusions, which later appear in comprehensive genomic profiling (CGP), the patient may experience considerable anxiety concerning the delay in receiving more effective personalized treatment.
Addressing these challenges requires improving communication between physicians and patients. Healthcare providers should clarify the reasons behind the choice of the type of test used (SGT) and the importance of understanding the potential harms of not conducting more comprehensive tests in the early stages of diagnosis. Patients should feel that their treatment options are based on accurate and reliable information, allowing them to choose the most suitable treatment path.
Patients’ Perspectives on Conflicting Test Results
Patients’ experiences in understanding conflicting test results are based on a variety of emotions that can significantly interfere with their mental state. Patients may experience anxiety when they realize that a different test could have led to alternative treatment options. This requires physicians to engage with patients, express empathy, and understand the feelings they are experiencing. For example, if a patient is aware that they could have received a more targeted treatment earlier, this may evoke feelings of regret and negative emotions regarding their previous healthcare experiences.
It requires
This situation calls for healthcare providers to be more aware of how tests impact the treatment pathway. Patients also need to understand the implications of making decisions regarding their tests, which contributes to empowering them to advocate for their rights to coordinated and comprehensive care. If healthcare providers can clarify the differences between SGT and CGP in practical context, patients may feel better equipped to make important treatment decisions in their therapeutic journey.
The Importance of Communication Between Doctors and Patients in Treatment Planning
Effective communication is considered one of the essential elements in improving treatment outcomes for patients with non-small cell lung cancer. Doctors must be able to provide clear and accurate information regarding the diagnosis and available tests. Building trust between doctors and patients significantly contributes to enhancing interaction and patient understanding of their options. Doctors should bear in mind that patients need to know how different tests work, alongside their benefits and drawbacks.
If doctors are committed to explaining how decisions regarding tests are made and addressing concerns, this helps patients feel more comfortable and empowered. For instance, discussing comprehensive genomic testing (CGP) as a superior option can help patients understand why doctors prefer this test over others. It is important for patients to understand why undergoing new tests can be beneficial, and their physician should be able to clarify this in simple terms.
Critique of Single Gene Tests versus Comprehensive Genomic Analysis
Opinions vary regarding the efficiency of single gene tests compared to comprehensive genomic profiling. While single gene tests (SGT) are considered to be lower in cost, comprehensive genomic profiling (CGP) may provide broader and more accurate insights into potential genetic mutations in a patient’s tumor. Many criticisms of traditional tests such as SGT can be attributed to their lack of precision in integrated therapeutic projections, which may lead to deterioration of the patient’s condition or delayed necessary treatment.
Evidence confirms that comprehensive genomic profiling provides an opportunity to discover potentially significant mutations that traditional tests might miss. This enhances patients’ chances of receiving personalized treatments based on the individual characteristics of their tumor, thereby increasing the likelihood of effective treatment. Hence, treatment decisions should be based on comprehensive data to ensure the highest possible success rate of therapy.
The Importance of Comprehensive Genetic Screening in Non-Small Cell Lung Cancer
In recent years, there has been a significant shift in the treatment of non-small cell lung cancer (NSCLC) towards targeted therapies supported by genetic testing. The traditional treatment plan based on generalized chemotherapy is insufficient due to the pathological and molecular complexity of the disease. Comprehensive genomic profiling (CGP) helps identify genetic mutations that play a role in disease progression and assists in guiding the correct treatment choice. According to statistics, NSCLC accounts for approximately 85% of all lung cancer diagnoses, making it one of the most prominent medical and therapeutic challenges in this field.
Comprehensive genetic testing can overcome the limitations associated with single gene tests (SGT), such as the inability to detect certain genetic mutations due to sequencing restrictions. In many cases, the use of SGT has led to incomplete or inconsistent results, where a small sample of tissue was used that may need to be utilized in other tests. In contrast, CGP provides a comprehensive analysis of a wide array of genetic mutations in a single test, reducing the consumption of depleted tissue.
The case stories presented in this context are clear examples of the practical benefits of using CGP in NSCLC diseases. Through a data-driven study conducted with reference laboratories like Labcorp, we were able to determine how patients respond differently to various screening methods. Each case demonstrates how the results obtained from CGP were more precise and efficient in guiding treatment compared to SGT. This reflects the increasing trend towards adopting comprehensive genetic testing as a better approach to delivering appropriate healthcare.
Challenges
Related to Single Gene Testing (SGT)
Although single gene testing is usually considered less expensive and faster in results compared to comprehensive genetic screening, it has several drawbacks. One of the fundamental considerations is that SGT relies on the analysis of only a specific gene or group of genes, which can lead to the loss of much information about other potential genetic mutations that may impact the disease course. Negative SGT results may frustrate patients and make them feel anxious, as these tests miss discovering genetic variants that may respond to targeted therapy.
It’s also important to note that individual genetic testing may yield inaccurate results if the sample is inadequate or if certain genetic mutations are associated. Furthermore, SGT may exhaust the biological samples needed for additional testing if necessary, affecting the ability to obtain accurate and comprehensive information about the patient’s condition in the future, even as the disease progresses.
Therefore, relying on SGT poses a significant barrier for some patients, especially when discussing advanced cases where greater scrutiny of the genetic condition of tumors is required. CGP, as a better alternative, addresses these issues more effectively as it allows healthcare professionals to access comprehensive and multi-faceted information about genetic variations, enabling them to make informed treatment decisions based on accurate results.
The Shift Towards Precision Medicine and Its Impact on Patients
With advances in science and the development of genetic testing technologies, the shift towards precision medicine emerges as a fundamental step in managing non-small cell lung cancer. Precision medicine relies on using genetic information and other biological data to tailor treatment for each patient individually, making therapeutic effects more effective and less exposed to side effects. Laboratories like Labcorp conduct more in-depth and professional analyses in line with this trend.
Recent studies have shown that patients who underwent comprehensive genetic testing and benefited from targeted therapies reported better outcomes in their quality of life and treatment response. For example, certain mutations like EGFR or ALK can benefit from specific medications such as tyrosine kinase inhibitors, improving survival rates.
Moreover, precision medicine gives patients a greater sense of control and improves the quality of healthcare they receive. With accurate information available, patients feel empowered to participate in decision-making regarding their treatment, reinforcing their belief in the success of the therapy. Genetic testing can significantly affect the mental health of the patient, as they receive the necessary support in their treatment journey.
The importance of applying techniques like CGP in clinical practice is increasing, and thus, in the future, we may witness a significant shift in how lung cancer and other tumors are managed. This trend could lead to improved expected outcomes, reduced long-term costs on the healthcare system, and more effective medical care for patients.
Additional Features and Benefits of Comprehensive Genetic Testing
Comprehensive genetic testing offers several additional advantages compared to single gene tests, as it can help identify rare genetic mutations that may be missed in traditional screenings. These advantages include the possibility of discovering previously unknown mutations that could lead to new treatment options, granting doctors the ability to develop more successful and effective treatment strategies.
Furthermore, modern technologies, such as next-generation sequencing, allow for the application of CGP more quickly and at lower costs than before. This development is particularly important in advanced cancer cases where time is a critical factor. Results can be obtained more quickly when applying CGP, enabling doctors to begin targeted therapy as soon as possible.
Also,
These tests can contribute to expanding the categories of drugs available to patients by discovering more therapeutic targets. Mutations that were previously unknown can lead to new drugs in the market targeting those mutations, providing patients with more options. Additionally, the vast diversity of targeted drugs makes it easier to choose the appropriate treatment based on what the genetic test reveals.
In conclusion, it appears that comprehensive genetic testing is not just a trend in treating non-small cell lung cancer, but represents a fundamental shift in how lung cancer is understood, as well as how care is tailored for patients. As knowledge in oncology and genetic medicine expands, a greater shift in how this acute disease is managed in the future is likely to occur.
Analysis of Genetic Testing Methods for Cancer
The main topic in genetic testing for cancer involves the use of the TruSight® Oncology 500 technology, which was developed by Illumina in San Diego, California. This technology is characterized by its ability to extract and analyze DNA and RNA from cancerous tissues preserved in formalin (FFPE). This method provides comprehensive information about genetic mutations occurring in 523 genes, including small mutations, insertions, and deletions of genetic information. Additionally, 59 genes are analyzed to determine changes in gene copy numbers, facilitating the detection of fusions and changes in splice sites between specific genes, as well as evaluating PD-L1 expression, which is a crucial indicator in immune response and immunotherapy. All results are presented in a comprehensive report that reveals vital information related to the disease state. This system offers significant benefits in understanding the genetic changes in patients, allowing for better management of treatment pathways.
The Importance of Comprehensive Genomic Profiling (CGP) in Lung Cancer Cases
Involvement from healthcare providers, including oncologists and pathologists, in a study involving 561 patients with advanced or metastatic non-small cell lung cancer demonstrates the significance of Comprehensive Genomic Profiling (CGP). Four patients were identified who had negative results from traditional tests, but actionable genetic changes were discovered through CGP. Managing cancer cases requires advancements in clinical research and diagnostic technology to understand the impact of mutations on treatment response. Comprehensive genomic profiling is considered a powerful tool because it can identify a large number of genetic mutations simultaneously, making it easier to determine appropriate targeted therapies that may be missing from traditional tests. This illustrates how analyzing results from multiple tests can improve medical care and increase the rate of recovery.
Case Studies and Challenges of Traditional Genetic Testing
Four case studies demonstrate how CGP surpasses traditional genetic tests such as FISH and PCR. Each case shows specific challenges in traditional testing techniques that may miss vital information related to genetic changes. For example, in the first case, traditional testing shows no actionable mutations despite positive tests for genetic fusions affecting the treatment strategy. In another case, CGP revealed an EGFR mutation that was previously unknown, significantly altering treatment pathways. Through these examples, it becomes clear that traditional genetic tests, such as SGT, are no longer sufficient to accommodate the increasing volume of knowledge regarding precise diagnosis and personalized treatment.
Conclusions on Developments in Gene Testing
As cancer research progresses, the importance of relying on comprehensive genomic profiling as a fundamental part of the lung cancer treatment strategy increases. Traditional genetic testing cannot detect many new mutations or significant changes that could be crucial in making treatment decisions. The analysis shows new approaches that use sustained research to understand the multiple implications of mutations, particularly in the context of immunotherapy. Insurance against unemployment and government programs that facilitate access to these technologies become essential to ensure all patients can benefit from advancements in targeted treatments. Therefore, reliance on CGP technologies is considered a strategic option that enhances the success rate in treating patients and achieving better outcomes during the treatment phase.
Challenges
Related to the use of traditional methods for identifying genetic mutations
Clinical research in the field of oncology faces numerous challenges regarding the efficiency and effectiveness of traditional methods for identifying genetic mutations. A recent study indicates that some patients with specific genetic mutations such as EGFR and ALK mutations may not benefit from immune therapies based on PD-1/PD-L1 inhibitors. According to NCCN guidelines, the use of these inhibitors is not recommended for patients with classical EGFR mutations, such as exon 19 deletions and L858R mutations. These guidelines provide strong evidence for the necessity of carefully selecting diagnostic methods based on the genetic characteristics of the patient.
Traditional genetic analyses are often insufficient in certain cases, as identifying specific cases requires multiple tests that may deplete patient tissues, complicating the treatment process. For instance, in one case, traditional genetic testing (SGT) was used to analyze a case that failed to detect significant genetic mutations, while whole genome sequencing (CGP) was able to identify mutations that were not only novel but also treatable with targeted medications. This led to improved treatment outcomes and offered new hope to the patients.
The importance of comprehensive genomic analysis in treatment personalization
Comprehensive genomic analysis is regarded as an advanced tool that provides substantial practical benefits in cancer diagnosis. This analysis provides a comprehensive platform that enables the identification of a wide spectrum of targetable genetic alterations. In a particular case, CGP was used to identify a MET exon 14 mutation, allowing for the use of targeted tyrosine kinase inhibitors. This type of analysis provides more comprehensive information compared to traditional analyses, thereby effectively contributing to the personalization of treatment based on individual tumor characteristics.
Furthermore, the practical benefit lies in reducing the need for multiple diagnostic tests, helping to preserve tissues available for other tests. In the case of lung cancer, tissue biopsies are often limited, thus CGP brings tremendous benefits in terms of tissue preservation and optimal utilization. This allows physicians to maximize the available tissue without the need for re-sampling, reducing patient suffering and exposure to additional risks.
Patients’ perspectives in treatment decision-making
The patients’ perspective holds significant importance in the treatment decision-making process, as conflicting test results can substantially affect their feelings and responses to treatment. If ALK mutations are not detected using traditional genetic analysis, a patient may feel relieved to discover they can receive a more effective treatment, yet they might also be concerned about the delay in accessing this targeted therapy. Patients’ understanding of the technology used in CGP and SGT testing increases their awareness of available treatment options and how comprehensive testing can impact their treatment course.
If the request for CGP is delayed, as has been the case in some instances, patients may feel that they have lost the opportunity to benefit from appropriate treatment in a timely manner. It is important for healthcare providers to communicate clearly with patients about the rationale behind the choice of test types and what that may lead to in terms of available treatment options. Healthcare providers should facilitate information regarding the importance of comprehensive genomic analysis and explain how advanced technologies can lead to more impactful outcomes in patient treatment.
Future challenges in adopting comprehensive genomic analysis
Despite the significant benefits that comprehensive genomic analysis offers, there are numerous barriers that limit its widespread adoption in clinical practices. These barriers include perceptions of high costs, the need for advanced sequencing equipment, and the requirement for specialized bioinformatics support to analyze complex data. Furthermore, reimbursement rates may be low, making some practices hesitant to adopt this new technology.
In
In conclusion, the importance of CGP is increasing as our understanding of cancer genomes evolves and the costs of analysis decrease. However, breakthroughs in this field require continuous education and close collaboration between physicians and researchers to understand genetic changes and their impact on future therapies. Therefore, research efforts should be intensified to clarify the clinical significance of some known genetic mutations, facilitating physicians in developing effective targeted therapeutic strategies.
Tumor Data Analysis Using Comprehensive Genome Techniques
Modern genomic data analysis techniques are core methods for identifying genetic changes and alterations contributing to tumor development, particularly non-small cell lung cancer (NSCLC). One of the major research areas is comprehensive genetic characterization, which allows physicians to understand the broad spectrum of genetic alterations that may affect patient response to treatment. These techniques include the use of methods such as whole genome sequencing, which provide insights into mutations, rearrangements, and gene expression in cancer cells.
Both genetic composition and data analysis play a significant role in improving diagnosis and targeted therapies. By using genetic sequencing data, physicians can identify predictive factors for treatment response, enabling them to design individualized treatment plans that include specific cancer-fighting drugs. For example, if an EGFR mutation is identified in a patient, EGFR inhibitors can be used as part of treatment strategies. These strategies are not only more effective but also reduce unnecessary side effects.
Recent research indicates an urgent need to adopt this technology in clinical practices, improving survival chances for patients. However, challenges remain regarding the cost of genetic testing and the need for more training for physicians in interpreting results. Therefore, investment in education and development in this area would have a significant impact on treatment outcomes.
Genetic Testing and Therapy Guidance for Non-Small Cell Lung Cancer
There are numerous genetic tests available for addressing non-small cell lung cancer cases, helping to identify optimal treatment options. A common technique used is single gene testing, which focuses on the specific capture of mutations in a particular gene. However, this method is associated with several limitations, as it may miss many important genetic changes.
In contrast, comprehensive genomic testing provides clearer insight into all existing changes in the genome, allowing the medical team to design personalized treatment. Advances in genetic sequencing technology have significantly contributed to reduced testing costs and efficiency, enabling physicians to target therapies more accurately. An example of this is the use of tyrosine kinase inhibitors to treat patients who exhibit specific mutations affecting growth receptors.
There is also a need to establish precise protocols for understanding how to integrate genetic testing results with current treatment options, requiring collaboration between physicians and researchers in both clinical and laboratory settings. These cases require a comprehensive assessment of gene expression levels, the specific type of mutations, and their impact on future treatment options. The better the current understanding of using genetic tests, the more effective the treatments will be, and the shorter the wasted time intervals.
Ethical Challenges in Using Genetic Data
As genetic testing technologies advance, a range of ethical challenges arise that must be taken into consideration. Among these challenges are privacy and personal data protection. Genetic data is highly sensitive, and its existence can lead to discrimination or misconceptions in certain social environments. Therefore, it is vital to establish clear policies to protect this information and ensure it is not used in harmful contexts.
There are also…
Also, questions related to informed consent, where patients need to have a complete understanding of the risks and benefits of genetic testing before making a decision. There must be simple and inclusive language to enable patients to understand the details of the tests and procedures. In addition, health institutions need to train their staff on how to appropriately and ethically handle these situations.
Perspectives on ethics and the approach towards the use of genetic data can vary among different cultures, reflecting the need for comprehensive awareness and delivering accurate information to patients about their rights and the implications of their data. Thus, trust can be strengthened between patients and doctors, contributing to the success of treatment interventions and progress towards a comprehensive willingness for genetic testing as a promising therapeutic tool.
Source link: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1445668/full
Artificial intelligence was used ezycontent
Leave a Reply